Home » Topics » Conferences, BioWorld Science

Conferences, BioWorld Science
RSS

OPC-21268 improves glomerulonephritis in hypercholesterolemic rats, nephropathy in diabetic rats

Nov. 13, 1998

Serum complement activation is implicated in the pathogenesis of CHF

Nov. 13, 1998

Vasopressin V2 receptor antagonist beneficial in mouse model of PKD

Nov. 13, 1998

VPA-985 characterized as potent, selective, orally active V2 antagonist

Nov. 13, 1998

BG-9719 has potent natriuretic effects in patients with CHF

Nov. 13, 1998

McMaster University researchers target potential gene therapies for arthritis

Nov. 13, 1998

Bristol-Myers Squibb initiates phase III HBV clinical trials; phase II data reported

Nov. 13, 1998

SB-205553 used to investigate role of 5-HT2C receptor antagonists in PD therapy

Nov. 13, 1998

Leflunomide reduces symptoms of rheumatoid arthritis, slows disease progression in new studies

Nov. 13, 1998

First clinical results reported for novel gene therapy in coronary artery disease

Nov. 12, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
JPM 2026: Year kicks off with biopharma Q4 revenue and guidance
BioWorld
It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...